Repligen | RGEN - Cash And Equivalent

Stock Price
141.83
Daily Change
-4.28 -2.93%
Monthly
-17.67%
Yearly
-12.37%
Q1 Forecast
144.77

Repligen reported $748.75M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agilent USD 1.79B 254M Sep/2025
Align Technology USD 1B 103.43M Sep/2025
Bio Techne USD 172.88M 27.92M Dec/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Bruker USD 293.1M 201.1M Sep/2025
Charles River Laboratories USD 207.1M 24.27M Sep/2025
Danaher USD 4.62B 3.09B Dec/2025
Dentsply International USD 363M 4M Sep/2025
Exact Sciences USD 789.04M 131.94M Sep/2025
General Electric Aerospace USD 12.39B 109M Dec/2025
Henry Schein USD 136M 9M Sep/2025
Illumina USD 1.05B 116M Sep/2025
IQVIA Holdings USD 1.98B 166M Dec/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Repligen USD 748.75M 39.89M Sep/2025
Revvity USD 931.39M 60.46M Sep/2025
Standard Biotools USD 129.42M 29.2M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Waters USD 459.12M 91.9M Sep/2025
West Pharmaceutical Services USD 628.5M 118.8M Sep/2025